Santaris Pharma this week announced additional data from its phase IIa trial of miravirsen, its locked nucleic acid-based miR-122 inhibitor for the treatment of hepatitis C.
In the trial, treatment-naive HCV patients received weekly doses of the drug at either 3 mg/kg, 5 mg/kg, or 7 mg/kg levels over 29 days via subcutaneous injection.
Of the nine patients treated at the highest dose, four became HCV RNA undetectable during the study, Santaris said. Additionally, the therapy resulted in a mean reduction of 2 to 3 logs from baseline RNA levels, which was maintained for more than four weeks after the end of treatment.
"These data ... show that longer duration of miravirsen monotherapy has the potential to produce sustained virological responses,” Harry Janssen, lead investigator of the study, said in a statement.
The data were presented at the this month's meeting of the American Association for the Study of Liver Diseases. Additional data were presented ahead of the meeting last month (GSN 10/6/2011).